Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
about
Pharmacology and Clinical Drug Candidates in Redox MedicineNrf2 Is an Attractive Therapeutic Target for Retinal DiseasesThe evidence for natural therapeutics as potential anti-scarring agents in burn-related scarringImprovements in the Management of Diabetic NephropathyAntioxidants in Translational MedicineThe paradox of bardoxolone methyl: a call for every witness on the stand?Role of Nuclear Factor Erythroid 2-Related Factor 2 in Diabetic Nephropathy.Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.Redox-based therapeutics in neurodegenerative disease.Discontinued in 2013: diabetic drugs.Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.Bardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat DietNovel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Synthetic Triterpenoid Inhibition of Human Ghrelin O-Acyltransferase: The Involvement of a Functionally Required Cysteine Provides Mechanistic Insight into Ghrelin Acylation.Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor.T-type calcium channel blocker attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis by activating the Nrf2 antioxidant pathway.Hyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus.Therapies on the Horizon for Diabetic Kidney Disease.Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells.Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.Oleanane derivatives for pharmaceutical use: a patent review (2000-2016).Novel avenues for treating diabetic nephropathy: new investigational drugs.Oleanolic Acid Alters Multiple Cell Signaling Pathways: Implication in Cancer Prevention and Therapy.NRF2 and NF-κB mRNA expression in chronic kidney disease: a focus on nondialysis patients.A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE.Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.Reviving the promise of transcription factor Nrf2-based therapeutics for kidney diseases.Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.Nrf2, the Master Regulator of Anti-Oxidative Responses.Nrf2 at the Heart of Oxidative Stress and Cardiac Protection.Effects of captopril, telmisartan and bardoxolone methyl (CDDO-Me) in ischemia-reperfusion-induced acute kidney injury in rats: an experimental comparative study.Bardoxolone-the Phoenix?Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.Insulin Inhibits Nrf2 Gene Expression via Heterogeneous Nuclear Ribonucleoprotein F/K in Diabetic Mice.Cardiovascular Safety in Drug Development: A Role for Endothelial Function Tests.Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice.
P2860
Q26785525-1D3B901D-83D6-4A21-8E7F-B40E1F6E7E26Q28077181-8CDCC455-645D-47B1-9458-FA64E910DE94Q28077410-3C7D2560-A02F-4B4D-B394-7BF1C8A424F0Q28080717-ECEE62AE-646A-4C87-BD6E-EF5936CF4B27Q28394550-56E948FE-A140-4956-8B11-1F5EBE965304Q33358784-8A593940-CADE-4826-935B-6BE0E6BBC067Q33645497-0CCE01A3-4E0B-45B9-9A63-3551E1FE8FA7Q34415403-B3450998-106F-4820-A743-FFA196751A43Q34535918-AC2E4C71-B3DF-4271-9DB6-FB10CE614685Q34664870-4315E988-4EC4-4EFB-944C-1FA3E8DDD03AQ35111445-2AC47D47-94CD-445F-A1C8-970A6EE796B1Q35808984-229F56B4-FE3E-4F46-A793-37BFCCD16E2CQ35953867-B1A421CF-BA5D-442C-9EB2-A009F70FCA1CQ36263619-5537CAD7-6823-4035-8B9F-704F91ACAE69Q36364169-2CCA3892-081F-485B-80E0-BDFCCC1C4A2DQ36463474-5549D854-AE9A-4353-A7BA-78DCCC1F1C20Q37448061-C0CB049E-4413-4397-8FF8-785700EF9B62Q37676355-19E425E0-BD71-46EC-8FC3-1AEB1E195C4CQ38605099-F7EBCEE0-B4A5-45C9-B25A-B6AAF4B6DE2BQ38712952-6CC5BE35-2AF2-472D-84D8-2D242044E771Q38786854-B1241AE0-CBDE-4E75-8E76-FAE9FAB0AC6DQ38906256-C27299B9-874C-4213-B733-4B1B120D32B0Q38991118-1C91B291-4C3C-4A14-ABF0-93C5B4CB7832Q39170387-E4B0D8BE-41AF-40C6-BBF2-51F5CD9DAD6EQ39181821-C63EFD9C-9C59-4D5A-B64A-4B18F4F82E26Q40404731-0CA556D7-CFA3-4E58-8272-3D67CDF6D7DCQ41549202-20ABC479-F7FB-4655-B780-33ED6FC72D42Q41634246-ABBBC65B-9FB8-487D-A364-03F0323FC49DQ42327949-8ED66F93-48B2-45FE-828B-228265C6BDC9Q44545402-BE70E683-7A5A-4C16-8C40-1676CC1FE179Q47250925-EB876AAB-E2BA-4374-9C4A-66A09E10CCB4Q47350229-942245CB-093E-480A-9D4F-C2A40DD5A054Q48111922-BF98F108-007D-411F-8F43-F0E519B91451Q49680688-A2901BE2-E639-4B1E-8A99-D1D891F3147BQ50198506-85605EEC-AAF2-4682-8549-CDC84C72C30BQ51092133-8E8C8441-D2DD-4E71-AF02-CA0DBBCC26A9Q53139178-5A42DC2A-83CA-4638-81C7-6E104A0E9CD6Q53653076-E6F9B168-06C9-42B8-B4D9-A293A000BC0C
P2860
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@ast
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@en
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@nl
type
label
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@ast
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@en
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@nl
prefLabel
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@ast
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@en
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@nl
P2093
P921
P356
P1476
Mechanisms contributing to adv ...... eated with bardoxolone methyl.
@en
P2093
Colin J Meyer
David G Warnock
David Packham
George L Bakris
Keith W Ward
Megan O'Grady
Melanie P Chin
Nosratola D Vaziri
Peter A McCullough
Peter G Linde
P304
P356
10.1159/000362906
P577
2014-06-03T00:00:00Z